Humacyte HUMA
NASDAQ HUMA
$0.59 +0.00 (+0.29%)
At close: Nov 11, 2026 · 4:00 PM EST

Humacyte (HUMA) Gains from Sales and Divestitures (2020 - 2024)

Updated

Humacyte (HUMA) recorded Gains from Sales and Divestitures of -$5,000 in FY2025, compared with -$4,000 in FY2024.

Analysis

Humacyte (HUMA) Gains from Sales and Divestitures (2020 - 2024) Analysis & Trends

Starting with FY2020, Humacyte's Gains from Sales and Divestitures history includes 5 years.

  • Annual Gains from Sales and Divestitures has ranged from -$18,000 in FY2023 to -$4,000 in FY2024 over the past five years.
  • Per Business Quant data, HUMA's Gains from Sales and Divestitures was -$4,000 in FY2024, -$18,000 in FY2023 and -$6,000 in FY2022.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Humacyte 163.90 Mn -213.24 Mn -401,000.00
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 -4,000.00
Dec 31, 2023 -9,000.00
Dec 31, 2020 -22,000.00
API Access

Humacyte Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=HUMA&period=max&api_key=YOUR_API_KEY